Business
Lattice Biologics Participates in $300 Million Public-Private Initiative, the Advanced Regenerative Manufacturing Institute (ARMI)
Lattice Biologics Participates in $300 Million Public-Private Initiative, the Advanced Regenerative Manufacturing Institute (ARMI).
About this update from Lattice Biologics Ltd
[{"type":"text","content":"\nLattice Biologics Participates in $300 Million Public-Private Initiative, the Advanced Regenerative Manufacturing Institute (ARMI)\n\nLattice Biologics Participates in $300 Million Public-Private Initiative, the Advanced Regenerative Manufacturing Institute (ARMI)\n\n\nInitiative aims to develop scalable manufacturing processes for engineered tissue and organs\n\n SCOTTSDALE, AZ--(Marketwired - February 28, 2017) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (\"Lattice Biologics\" or the \"Company\") is pleased to announce that it is part of a new public-private initiative, the Advanced Regenerative Manufacturing Institute (\"ARMI\"). ARMI will receive approximately $80 million from the federal government, which will be combined with more than $200 million in non-federal cost share, to establish the Advanced Tissue Biofabrication Manufacturing USA Institute. Headquartered in Manchester, New Hampshire, this new Institute brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for life-saving cells, tissues and organs.This effort will provide support to help bridge the gap between basic/early research and product development by advancing and scaling critical biofabrication technologies, and will provide shared assets to help entities access cutting edge capabilities and equipment.In collaboration with key individuals at ASU Biodesign in Tempe, Arizona, Lattice Biologics is developing products, which include the use of scaffolds derived from human tissue that can 1) support ingrowth of tissue progenitor cells (notably, stem cells), 2) direct and preserve the phenotypes of engrafted cells and 3) enhance healing times and improve patient outcomes. Underlying these efforts is the use of ECM (extracellular matrix) secreted by stem cells and/or harvested from various tissues including muscle, adipose and placenta, to develop game-changing technologies in the field of regenerative medicine.As an emerging leader in the field of cellular therapies and tissue engineering, Lattice Biologics will play an important role in ARMI's mission to develop innovative manufacturing capabilities by sharing strategic research and development efforts, provide source biomaterial for testing and bring toge...